Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Brincidofovir versus standard of care for adenovirus infection after pediatric allogeneic HCT
NL-OMON46433Phase 2Withdrawn
- Sponsor
- Chimerix Inc.
- Start
- Apr 2018
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in adenoviral infection comparing Brincidofovir with Standard of care (2 arms). Primary endpoint: Area under the adenovirus viremia curve through Week 16. Planned start Apr 2018; status: withdrawn.
02
Drugs
brincidofovir
03
Conditions
adenoviral infection
Beyond the preview
Go deeper on NL-OMON46433.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46433.